Centessa Pharmaceuticals (NASDAQ:CNTA) Shares Down 4.4%

Centessa Pharmaceuticals plc (NASDAQ:CNTA)’s stock price traded down 4.4% during trading on Thursday . The stock traded as low as $9.41 and last traded at $9.46. 72,870 shares traded hands during mid-day trading, a decline of 76% from the average session volume of 307,556 shares. The stock had previously closed at $9.90.

Analyst Ratings Changes

Several equities analysts recently issued reports on CNTA shares. BMO Capital Markets reiterated an “outperform” rating and set a $15.00 price target on shares of Centessa Pharmaceuticals in a research report on Monday, April 1st. Morgan Stanley raised their target price on Centessa Pharmaceuticals from $8.00 to $11.00 and gave the company an “equal weight” rating in a research note on Friday, June 21st. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $10.50.

Centessa Pharmaceuticals Stock Down 3.3 %

The company has a debt-to-equity ratio of 0.36, a current ratio of 10.37 and a quick ratio of 10.37. The stock’s 50 day simple moving average is $8.95 and its two-hundred day simple moving average is $9.39. The firm has a market cap of $961.59 million, a P/E ratio of -7.08 and a beta of 1.40.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its quarterly earnings data on Monday, May 13th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.03. As a group, research analysts forecast that Centessa Pharmaceuticals plc will post -1.67 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of CNTA. China Universal Asset Management Co. Ltd. lifted its position in Centessa Pharmaceuticals by 69.2% during the first quarter. China Universal Asset Management Co. Ltd. now owns 10,817 shares of the company’s stock valued at $122,000 after purchasing an additional 4,423 shares during the period. Quarry LP bought a new position in shares of Centessa Pharmaceuticals during the 4th quarter valued at $48,000. EntryPoint Capital LLC bought a new position in shares of Centessa Pharmaceuticals during the 1st quarter valued at $109,000. Jump Financial LLC purchased a new position in shares of Centessa Pharmaceuticals in the 4th quarter worth $114,000. Finally, Trexquant Investment LP bought a new stake in shares of Centessa Pharmaceuticals in the fourth quarter worth $114,000. 82.01% of the stock is owned by institutional investors.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.